1. Home
  2. FCCO vs SLN Comparison

FCCO vs SLN Comparison

Compare FCCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Community Corporation

FCCO

First Community Corporation

HOLD

Current Price

$30.07

Market Cap

290.5M

Sector

Finance

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.92

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCCO
SLN
Founded
1994
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
290.5M
236.2M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
FCCO
SLN
Price
$30.07
$6.92
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
61.4K
174.2K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
2.16%
N/A
EPS Growth
36.46
N/A
EPS
0.59
N/A
Revenue
$922,000.00
N/A
Revenue This Year
$30.67
N/A
Revenue Next Year
$5.87
N/A
P/E Ratio
$51.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.80
$4.19
52 Week High
$31.51
$8.40

Technical Indicators

Market Signals
Indicator
FCCO
SLN
Relative Strength Index (RSI) 52.26 52.19
Support Level $29.16 $5.76
Resistance Level $31.21 $7.53
Average True Range (ATR) 0.67 0.58
MACD 0.03 0.01
Stochastic Oscillator 56.64 66.18

Price Performance

Historical Comparison
FCCO
SLN

About FCCO First Community Corporation

First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: